Premium
Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa
Author(s) -
Ricceri Federica,
Rosi Elia,
Di Cesare Antonella,
Pescitelli Leonardo,
Fastame Maria Thais,
Prignano Francesca
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.14387
Subject(s) - hidradenitis suppurativa , adalimumab , medicine , dermatology , biosimilar , rheumatoid arthritis , disease
Adalimumab is the only biologic therapy approved for the treatment of patients with hidradenitis suppurativa, a chronic and disabling skin condition. To date, there are no studies in the literature about the effectiveness of adalimumab biosimilar SB5 in hidradenitis suppurativa. The aim of this study was to evaluate its efficacy and safety. A retrospective observational study was performed in hidradenitis suppurativa adalimumab naive patients and in patients who were switched from the adalimumab originator. Eleven patients were included in the study. Our results support adalimumab SB5 as an effective and well tolerated drug, with a good interchangeability with its originator also for the treatment of hidradenitis suppurativa.